Treatment options for androgenetic alopecia

被引:0
|
作者
Lazaridou, E. [1 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Dermatol 1, Thessaloniki, Greece
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Androgenetic alopecia (AGA) is a common, genetically determined, progressive disorder that affects both men and women. Available medical treatments prevent progression of the disease and reverse miniaturization of hair follicles. Only two proven and approved medications are currently in use for the treatment of AGA: the potassium channel opener minoxidil, applied topically and the dihydrotestosterone synthesis inhibitor finasteride, administered systemically. Other potentially helpful topical agents include a derivative of minoxidil - aminexil, or a combined preparation containing the patent RTH16 molecule. Other effective components are extracts from Sabal serrulata palm tree, a 5-alpha reductase blocker, and tocopheryl nicotinate, which increase blood circulation. Recently, topical antiandrogen fluridil which suppresses androgen receptors in hair follicles has been used. Drugs containing vitamins, aminoacids and trace elements may be used as supportive therapy. In women, drugs that act as antiandrogens (spironolactone, oral contraceptives) or topical preparations, which contain estrogens, may be beneficial. Surgical treatment of AGA with autotransplantation of hair often produces satisfactory cosmetic results.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 50 条
  • [41] TOPICAL MINOXIDIL IN THE TREATMENT OF ANDROGENETIC ALOPECIA IN WOMEN
    OLSEN, EA
    [J]. CUTIS, 1991, 48 (03): : 243 - &
  • [42] Controversies surrounding finasteride treatment for androgenetic alopecia
    Yip, L.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 11 - 11
  • [43] Thyroid receptor agonists for the treatment of androgenetic alopecia
    Li, Jie Jack
    Mitchell, Lorna H.
    Dow, Robert L.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (01) : 306 - 308
  • [44] Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options
    Vasserot, Alain P.
    Geyfman, Mikhail
    Poloso, Neil J.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (09) : 755 - 771
  • [45] Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia?
    Melo, Daniel Fernandes
    Ramos, Paulo Muller
    Antelo, Daniela Alves Pereira
    Machado, Carla Jorge
    Barcaui, Carlos Baptista
    [J]. JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (07) : 2093 - 2095
  • [46] Androgenetic Alopecia: An Evidence-Based Treatment Update
    Varothai, Supenya
    Bergfeld, Wilma F.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2014, 15 (03) : 217 - 230
  • [47] Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia
    Gupta, Aditya K.
    Cole, John
    Deutsch, David P.
    Everts, Peter A.
    Niedbalski, Robert P.
    Panchaprateep, Ratchathorn
    Rinaldi, Fabio
    Rose, Paul T.
    Sinclair, Rodney
    Vogel, James E.
    Welter, Ryan J.
    Zufelt, Michael D.
    Puig, Carlos J.
    [J]. DERMATOLOGIC SURGERY, 2019, 45 (10) : 1262 - 1273
  • [48] Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia
    Gupta, A. K.
    Carviel, J. L.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (06) : 643 - 647
  • [49] Manage androgenetic alopecia in men with established options but emerging therapies show promise
    Amy Zhuang-Yan
    Sheridan M. Hoy
    [J]. Drugs & Therapy Perspectives, 2023, 39 : 292 - 296
  • [50] Manage androgenetic alopecia in men with established options but emerging therapies show promise
    Zhuang-Yan, Amy
    Hoy, Sheridan M.
    [J]. DRUGS & THERAPY PERSPECTIVES, 2023, 39 (08) : 292 - 296